| __timestamp | Galapagos NV | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 9079000 | 17986000 |
| Thursday, January 1, 2015 | 20309000 | 32480000 |
| Friday, January 1, 2016 | 16945000 | 68081000 |
| Sunday, January 1, 2017 | 20559000 | 169906000 |
| Monday, January 1, 2018 | 29641000 | 248932000 |
| Tuesday, January 1, 2019 | 88258000 | 354100000 |
| Wednesday, January 1, 2020 | 162170000 | 433300000 |
| Friday, January 1, 2021 | 167218000 | 583300000 |
| Saturday, January 1, 2022 | 239528000 | 752700000 |
| Sunday, January 1, 2023 | 94252000 | 887600000 |
| Monday, January 1, 2024 | 1007200000 |
Cracking the code
In the competitive world of biotechnology, managing operational expenses is crucial for sustained growth. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Neurocrine Biosciences, Inc. and Galapagos NV from 2014 to 2023. Over this period, Neurocrine Biosciences consistently outpaced Galapagos NV in SG&A spending, with a peak in 2023 where their expenses were nearly 9 times higher. This trend reflects Neurocrine's aggressive expansion and investment in administrative capabilities.
Galapagos NV, on the other hand, exhibited a more conservative approach, with a notable spike in 2022, reaching 240% of their 2014 expenses. This could indicate strategic investments in marketing or restructuring efforts. Understanding these trends provides insights into each company's strategic priorities and operational efficiency. As the biotech landscape evolves, monitoring SG&A efficiency will remain pivotal for investors and stakeholders alike.
Comparing SG&A Expenses: Eli Lilly and Company vs Neurocrine Biosciences, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Novo Nordisk A/S and Galapagos NV
Selling, General, and Administrative Costs: AstraZeneca PLC vs Galapagos NV
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Neurocrine Biosciences, Inc.
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Neurocrine Biosciences, Inc.
Breaking Down SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Ultragenyx Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Catalyst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and Dynavax Technologies Corporation
Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of ADMA Biologics, Inc. and Galapagos NV